Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PreveCeutical Medical Inc. (PRVCF : OTC)

• Company Description    PreveCeutical Medical Inc. is a health sciences company which develops preventive therapies utilizing organic and nature identical products. The company's research and development programs includes dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical (TM) peptides for treatment of ailments; non-addictive analgesic peptides, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions. It sells CELLB9(R), an Immune System Booster. CELLB9(R) is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. PreveCeutical Medical Inc. is based in Vancouver, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.02 Daily Weekly Monthly 20 Day Moving Average: 40,065 shares Shares Outstanding: 570.65 (millions) Market Capitalization: $12.84 (millions) Beta: 0.34 52 Week High: $0.03 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.05% -19.19% 12 Week -6.64% -21.47% Year To Date 22.28% 14.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 885 Cambie Street Suite 2500 - Vancouver,A1 V6B 0R6 CAN ph: 604-416-7777 fax: 778-945-6290 ir@preveceutical.com http://www.preveceutical.com

• General Corporate Information    Officers Stephen Van Deventer - Chief Executive Officer; Chief Financial Officer a Mak Jawadekar - President Linnea Olofsson - Director Kathleen Rokita - Director C. Evan Ballantyne - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74141E104 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/04/25 Share - Related Items Shares Outstanding: 570.65 Most Recent Split Date: 5.00 (5.00:1) Beta: 0.34 Market Capitalization: $12.84 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©